Theravance Biopharma (TBPH) Non-Current Debt (2018 - 2022)

Theravance Biopharma (TBPH) has 5 years of Non-Current Debt data on file, last reported at $396.1 million in Q2 2022.

• Non-Current Debt for Q2 2022 came in at $396.1 million, up 5.61% year-over-year; the trailing twelve-month figure through Jun 2022 was $396.1 million (up 5.61% YoY), and the FY2021 annual result was $371.4 million, changed 0.41% from the prior year.
• Non-Current Debt improved to $396.1 million in Q2 2022 per TBPH's latest filing, from $384.2 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $396.1 million in Q2 2022 and troughed at $217.7 million in Q2 2019.
• A 5-year average of $326.3 million and a median of $373.9 million in 2020 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2019 and 2020: Non-Current Debt retreated 4.46% in 2019, then soared 73.18% in 2020.
• A 5-year view of Non-Current Debt shows it stood at $229.5 million in 2018, then dropped by 4.46% to $219.3 million in 2019, then jumped by 70.03% to $372.9 million in 2020, then decreased by 0.41% to $371.4 million in 2021, then grew by 6.67% to $396.1 million in 2022.
• Business Quant data shows TBPH's Non-Current Debt at $396.1 million in Q2 2022, $384.2 million in Q1 2022, and $371.4 million in Q4 2021.